NICE, the health technology appraisal institute for England and Wales, has at last recommended the use of Janssen's Zytiga (abiraterone) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy, three months after initially rejecting its use on the publicly funded National Health Service, due to inadequate cost-effectiveness and efficacy data.
The institute's volte face followed a reconsideration of the therapy's application after the Johnson & Johnson division submitted extra data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?